Analyst Price Target is $12.00
▲ +88.98% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Vallon Pharmaceuticals in the last 3 months. The average price target is $12.00, with a high forecast of $12.00 and a low forecast of $12.00. The average price target represents a 88.98% upside from the last price of $6.35.
Current Consensus is
The current consensus among 1 investment analysts is to buy stock in Vallon Pharmaceuticals.
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of prescription drugs for central nervous system disorders. The company develops abuse-deterrent amphetamine immediate-release, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. It also develops ADMIR, an abuse deterrent formulation of Ritalin. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.